Number of uHCC patients corresponding to atezolizumab+bevacizumab accessibility.

NIAID Data Ecosystem2026-05-01 收录

数据链接：

https://figshare.com/articles/dataset/Number_of_uHCC_patients_corresponding_to_atezolizumab_bevacizumab_accessibility_/25456019 数据链接链接失效反馈

官方服务：

资源简介：

Number of uHCC patients corresponding to atezolizumab+bevacizumab accessibility.

创建时间：

2024-03-21

A Retrospective-Prospective observational study in China to describe the management in clinical practice of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation who have received prior systemic therapy

BRAFV600E突变结直肠癌治疗路径

肿瘤真实世界研究

Interventions: Retrospective group:None;Prospective group:None Primary outcome(s): Describe the treatment path of the target population Study Design: Sequential

NIAID Data Ecosystem30

DataSheet_2_Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials.pdf

肿瘤真实世界研究

慢性粒细胞白血病预后评估

Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This ra

NIAID Data Ecosystem20

Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims data.

肿瘤真实世界研究

临床试验疗效验证

Supplemental Table 1. Comparison of inclusion and exclusion criteria with the CHAARTED trial. Supplemental Table 2. Codes for identification of diagnoses, drug prescriptions/administrations, and proce

DataCite Commons2022-05-03 更新20

意大利肿瘤药物监测登记与临床试验患者基线特征对比研究数据

肿瘤真实世界研究

患者基线特征

本数据集为意大利肿瘤药物监测登记与注册临床试验患者基线特征对比的原始数据，来自一项横断面真实世界研究。数据集包含一份Excel文件，记录了两类研究中患者的基线特征信息，可用于分析真实世界数据与临床试验数据的患者特征差异，为肿瘤药物研究提供参考。

海数据20

Number of uHCC patients corresponding to atezolizumab+bevacizumab accessibility.

肝细胞癌治疗可及性

肿瘤药物卫生经济学

Number of uHCC patients corresponding to atezolizumab+bevacizumab accessibility.

Figshare2024-03-21 更新20